ATE258228T1 - Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression - Google Patents

Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression

Info

Publication number
ATE258228T1
ATE258228T1 AT01124236T AT01124236T ATE258228T1 AT E258228 T1 ATE258228 T1 AT E258228T1 AT 01124236 T AT01124236 T AT 01124236T AT 01124236 T AT01124236 T AT 01124236T AT E258228 T1 ATE258228 T1 AT E258228T1
Authority
AT
Austria
Prior art keywords
expression
adenoviral
improve
gene expression
orf6
Prior art date
Application number
AT01124236T
Other languages
English (en)
Inventor
Majid Mehtali
Monika Lusky
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE258228T1 publication Critical patent/ATE258228T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
AT01124236T 1998-07-07 1999-07-01 Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression ATE258228T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98401722 1998-07-07
EP98402825 1998-11-13

Publications (1)

Publication Number Publication Date
ATE258228T1 true ATE258228T1 (de) 2004-02-15

Family

ID=26151663

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99401645T ATE225400T1 (de) 1998-07-07 1999-07-01 Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression
AT01124236T ATE258228T1 (de) 1998-07-07 1999-07-01 Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99401645T ATE225400T1 (de) 1998-07-07 1999-07-01 Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression

Country Status (11)

Country Link
US (1) US6475480B1 (de)
EP (2) EP0974668B1 (de)
JP (1) JP2000106875A (de)
AT (2) ATE225400T1 (de)
AU (1) AU756607B2 (de)
CA (1) CA2276791A1 (de)
DE (2) DE69914382T2 (de)
DK (2) DK0974668T3 (de)
ES (2) ES2180258T3 (de)
HK (1) HK1043390A1 (de)
PT (2) PT974668E (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225113B1 (en) * 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
EP1301612A2 (de) * 2000-05-31 2003-04-16 Genvec, Inc. Verfahren und zusammenfassung zur zielrichtung von adenoviralen vektoren
EP1203819A3 (de) 2000-10-06 2002-08-07 Transgene S.A. Entzündungshemmende Vektoren
US20040106194A1 (en) * 2002-08-22 2004-06-03 Bett Andrew J. Methods for propagating adenovirus and virus produced thereby
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
EP1831382B1 (de) * 2004-12-31 2023-01-18 Per Sonne Holm Verfahren zur aufhebung von mehrfachresistenz in tierzellen
WO2008073893A2 (en) * 2006-12-08 2008-06-19 Adv Technologies Llc Methods for producing an adenovirus type 5 gene transfer vector
US8465732B2 (en) 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
KR101667094B1 (ko) 2010-08-16 2016-10-17 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 항암 아데노바이러스
KR101522341B1 (ko) * 2012-10-02 2015-05-21 국립암센터 신규한 조건부-복제 가능 아데노바이러스 및 그의 제조 방법
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Gm−csfとil−4のコンジュゲート、組成物、ならびにそれに関連する方法
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
EP3390645B1 (de) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogene genexpression eines therapeutischen adenovirus mit geringem einfluss auf die virale kinetik
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EP3612556B8 (de) 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Verbesserte lamp konstrukte
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. アレルゲンを含む改善されたlamp構築物
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
CN110656090B (zh) * 2019-10-28 2023-06-30 嘉兴安宇生物科技有限公司 一种表达质粒、用于包装容量增加的二代腺病毒的细胞株及其应用
CN110714027A (zh) * 2019-10-28 2020-01-21 嘉铭(固安)生物科技有限公司 一种表达质粒、用于包装二代腺病毒的细胞株及其应用
WO2022007800A1 (zh) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 一种非洲猪瘟的重组腺病毒疫苗及其构建方法
JP7555643B2 (ja) * 2021-01-21 2024-09-25 株式会社 セリッド 複製能のあるアデノウイルスを包含しない新規アデノウイルスベクター、およびこれの使用
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP0673431A1 (de) * 1992-12-03 1995-09-27 Genzyme Corporation GENTHERAPIE DER MYKOVISCIDOSES (kystic fibroses)
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
WO1998021350A1 (en) * 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence

Also Published As

Publication number Publication date
ES2180258T3 (es) 2003-02-01
AU3800999A (en) 2000-06-08
DE69903229T2 (de) 2003-06-26
DK1199368T3 (da) 2004-04-13
DE69903229D1 (de) 2002-11-07
US6475480B1 (en) 2002-11-05
DE69914382D1 (de) 2004-02-26
HK1043390A1 (en) 2002-09-13
EP0974668A1 (de) 2000-01-26
ES2210081T3 (es) 2004-07-01
EP1199368B1 (de) 2004-01-21
ATE225400T1 (de) 2002-10-15
PT974668E (pt) 2003-01-31
EP0974668B1 (de) 2002-10-02
PT1199368E (pt) 2004-04-30
DK0974668T3 (da) 2002-11-11
JP2000106875A (ja) 2000-04-18
DE69914382T2 (de) 2004-11-04
AU756607B2 (en) 2003-01-16
EP1199368A2 (de) 2002-04-24
CA2276791A1 (en) 2000-01-07
EP1199368A3 (de) 2002-07-17

Similar Documents

Publication Publication Date Title
ATE225400T1 (de) Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression
PL397823A1 (pl) Sposób identyfikacji serotypu sekwencji wirusa stowarzyszonego z adenowirusem (AAV), zestaw diagnostyczny, sposób izolacji nowych wirusów, nowy serotyp wirusa, wyizolowane wirusy, białka obejmujące fragment białka kapsydu AAV, sztuczne białka, zrekombinowany wirus, cząsteczki, sposób wytwarzania zrekombinowanych wirusów, komórki gospodarza, kompozycje, sposób dostarczania transgenu, wyizolowany AAV, rekombinowana komórka, sposób wytwarzania rekombinowanego wirusa, zastosowanie wirusa
EP0851769A4 (de) Gentherapie mit hilfe von schaf-adenoviralen vektoren
IL199126A (en) Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters.
WO2001083692A3 (en) Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
PT1625210E (pt) Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios
CA2167578A1 (en) Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor
WO1998055639A3 (fr) Vecteurs adenoviraux recombinants comprenant une sequence d'epissage
EP1203819A3 (de) Entzündungshemmende Vektoren
EP0752888A4 (de) NUKLEOTID- AMINOSÄURESEQUENZEN DER HERPEVIREN gB,gC UND gD AUS HUND UND IHRE VERWENDUNGEN
DE69929530D1 (de) Attenuierte pferdeherpesvirus
ATE377087T1 (de) Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
JPH0773500B1 (de)
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
WO2006116267A3 (en) Cell-specific molecule and method for importing dna into osteoblast nuclei
WO2006086357A3 (en) Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
EP4407025A3 (de) Adenovirus mit modifiziertem adenovirus-hexon-protein
CHEN et al. STUDY OF GENES DIFFERENTIALLY EXPRESSED IN CD34~+ CELLS FROM G-CSF-MOBILIZED PERIPHERAL BLOOD AND BONE MARROW USING THE TECHNIQUE OF SUPPRESSION SUBTRACTIVE HYBRIDIZATION
ZHONG et al. Screening of binding protein of hepatitis C virus NS4A by phage display from human liver cDNA library
TANG et al. Cloning of P1 and P3 promoters of human insulin-like growth factorⅡ gene
CHE et al. Study of E-cadherin Antisense Oligodeoxynucleotide on Invasive Ability of Tumor Cells
LIN et al. Construction of recombinant adenoviruses carrying human hepatocyte growth factor and investigation of its effect on human fetal hepatocytes in vitro
LEE et al. Sequence Diversity of E2/NSl of Hepatitis C Virus from Koreans
ZHUANG et al. Relationship between genetic diversity of surface protein of Streptococcus mutans and dental caries. Ⅱ Sequence of V-region and P-region gene of surface protein of Streptococcus mutans
ZHANG et al. Expression of Epstein-Barr virus gene BARF1 in the nasopharyngeal carcinoma and its significance

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1199368

Country of ref document: EP

REN Ceased due to non-payment of the annual fee